Successful Drug Discovery -

. .

Sommaire:
PART I: GENERAL ASPECTS New Trends in Drug Discovery Patenting Small and Large Pharmaceutical Molecules PART II: DRUG CLASSES Kinase Inhibitor Drugs Evolution of Nonsteroidal Androgen Receptor Antagonists PART III: CASE HISTORIES Development of T-Cell-Engaging Bispecific Antibody Blinatumomab (Blincyto) for Treatment of B-Cell Malignancies Ceritinib: A Potent ALK Inhibitor for the Treatment of Crizotinib-Resistant Non-Small Cell Lung Cancer Tumors Discovery, Development, and Mechanisms of Action of the Human CD38 Antibody Daratumumab The Discovery of Obeticholic Acid (Ocaliva), First in Class FXR Agonist Discovery and Development of Obinutuzumab (Gazyva, Gazyvaro), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphotic Leukemia Omarigliptin (Marizev, MK-3102) Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor (COMT) to Manage the Symptoms of Parkinson's Disease The Discovery of Osimertinib (Tagrisso): An Irreversible Inhibitor of Activating and 1790M Resistant Forms of the Epidermal Growth Factor Receptor Tyrosine Kinase for the Treatment of Non-Small Cell Lung Cancer Discovery of Pitolisant, the First Marketed Histamine H3-Receptor Inverse Agonist/Antagonist for Treating Narcolepsy Discovery and Development of Safinamide, a New Drug for the Treatment of Parkinson's Disease Discovery and Development of Trifluridine/Tipiracil (Lonsurf)